Making safe sense of an anti-sense!

Gill, Upkar S; Lemoine, Maud · Cell Rep Med · 2022

editorial · Level V

Where this comes from

Abstract

Bepiroversen has been developed and trialed for the cure of HBV. Yuen et al.<sup>1</sup> report on the safety and antiviral efficacy of this agent. We "spotlight" key findings of this study and its impact for future clinical trial design.

Medical subject headings